TECTONIC THERAPEUTIC INC

Insider trades by TECTONIC’s CSO show disciplined, rule‑compliant rebalancing that signals governance strength and readiness for future partnerships in the high‑growth gene‑therapy arena.

CF‑opt insider move: Tectonic CFO buys 7,500 performance‑based shares, signaling confidence in 2026 milestones and potential upside for investors.

CEO’s zero‑cost RSU buy fuels insider confidence in Tectonic Therapeutics’ gene‑therapy pipeline and potential upside, but investors must weigh clinical milestones and FDA approvals.

CEO Reicin Alise’s recent purchase of 2,500 Tectonic Therapeutic shares shows executive confidence, hinting at future gene‑therapy milestones and a potential upside for investors.

CEO Reicin Alise’s recent 2,500‑share buy at $21.10 shows strategic confidence in Tectonic Therapeutics’ gene‑therapy pipeline, hinting at potential upside despite volatile pricing.

Executive insider buys Tectonic Therapeutics shares as breakthrough‑designated AML drug shows strong efficacy and safety, signaling confidence in its pipeline and potential market impact.